Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Cb27743on Dec 06, 2022 6:09pm
142 Views
Post# 35154714

RE:RE:RE:RE:RE:Silence

RE:RE:RE:RE:RE:SilenceI hear your frustration,
 
We are still waiting for reviewed data from their completed 2021 P2 trial which usually takes 6 from what I heard on another market platform. The last update we recieved from Management regarding the P2 trial was August 2021. Unless there is other material updates we are not aware of? We are almost into 2023 and still ghosted. Is this still being reviewed? was the data positive?


Insiders have bought more earlier this year and smaller amounts in spring/fall, which is a good sign regarding the company status IMO.   

And great question, their cash won't last forever, when do they plan on another raise? What is their plan? 







<< Previous
Bullboard Posts
Next >>